# Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

> **NCT03461952** · PHASE2 · TERMINATED · sponsor: **Canadian Cancer Trials Group** · enrollment: 4 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03461952
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-11
- **Primary completion:** 2021-06-01
- **Final completion:** 2022-02-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected. It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials.
- **Last updated:** 2024-02-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03461952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03461952, "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03461952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*